8-K: Corbus Pharmaceuticals Reports Positive Clinical Trial Updates and Secures $116 Million in Funding

Corbus Pharmaceuticals announced encouraging clinical data for its oncology pipeline, including CRB-701, CRB-601, and CRB-913, and secured significant funding to extend its cash runway.

Summary

• Corbus Pharmaceuticals provided a corporate update and reported financial results for the fourth quarter and year-end 2023.
• The company highlighted positive first-in-human data for CRB-701 presented at ASCO-GU, showing a 43% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) in Nectin-4 positive cancer patients at therapeutically relevant doses.
• The first patient in the US Phase 1 study for CRB-701 is expected to be dosed by the end of March 2024.
• The FDA cleared the Investigational New Drug (IND) application for CRB-601, with the Phase 1 study expected to commence in the summer of 2024.
• Pre-clinical data for CRB-913 was presented at Obesity Week, with an IND filing on track for the end of 2024.
• Corbus raised $116 million in capital in 2024, including $94.5 million from a public offering and $21.1 million from ATM sales.
• The company reported $127 million in cash and investments as of February 2, 2024, projecting a cash runway through Q1 2027.
• A new Chief Medical Officer, Dr. Dominic Smethurst, was appointed in February 2024.
• The company reported a net loss of $8.0 million for Q4 2023 and $44.6 million for the full year 2023.

Sentiment

Score: 8

Explanation: The document is largely positive due to the encouraging clinical trial results, successful capital raise, and clear development timelines. The appointment of a new CMO also adds to the positive sentiment. However, the company is still in the early stages of development and is loss making.

Positives

• The clinical data for CRB-701 is encouraging, showing a strong response rate and disease control in early trials.
• The FDA clearance of the IND for CRB-601 is a significant step forward for the program.
• The pre-clinical data for CRB-913 is promising, indicating potential for obesity treatment.
• The successful capital raise of $116 million significantly strengthens the company's financial position.
• The appointment of an experienced Chief Medical Officer is a positive development for the clinical pipeline.

Negatives

• The company reported a net loss of $8.0 million for Q4 2023 and $44.6 million for the full year 2023.
• Operating expenses for Q4 2023 were $10.1 million, although this was a decrease compared to the same period in 2022.

Risks

• The company is still in the early stages of clinical development for its pipeline, and there is no guarantee of success.
• Clinical trials are subject to regulatory risks and potential delays.
• The company is dependent on raising additional capital to fund its operations.
• The company faces competition from other pharmaceutical companies developing similar therapies.

Future Outlook

The company expects to dose the first patient in the US Phase 1 study for CRB-701 by the end of March 2024, commence the Phase 1 study for CRB-601 in the summer of 2024, and file an IND for CRB-913 by the end of 2024. They also expect to provide a clinical update for CSPCs dose-escalation study in mid-2024 and to present US dose escalation data by Q1 2025.

Management Comments

• In 2023 we made significant progress in advancing our pipeline to meaningful milestones.
• These efforts culminated in us strengthening our balance sheet by raising $116 million of capital in 2024 providing us with a projected runway of over 3 years, said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
• We expect to dose the first patient in our US Ph1 study in March 2024.
• For CRB-601, the FDA cleared our Investigational New Drug (IND) application in January 2024, and we expect to dose the first patient this summer.
• Finally, for CRB-913, we presented promising pre-clinical data at Obesity Week in October 2023 and are on track to file an IND by the end of 2024, concluded Dr. Cohen.

Industry Context

This announcement is positive for Corbus as it demonstrates progress in their clinical pipeline and secures funding to continue operations. The focus on precision oncology and the development of novel therapies for cancer and obesity aligns with current industry trends.

Comparison to Industry Standards

• The 43% ORR and 71% DCR for CRB-701 in Nectin-4 positive tumors is promising compared to other antibody-drug conjugates in similar stages of development, such as enfortumab vedotin, which has shown efficacy in urothelial cancer.
• The development of a TGF-blocking monoclonal antibody like CRB-601 is in line with the industry's focus on targeting the tumor microenvironment to enhance anti-cancer therapies, similar to other companies exploring checkpoint inhibitors and combination therapies.
• The pre-clinical data for CRB-913, a CB1 receptor inverse agonist, is comparable to other companies developing novel obesity treatments, such as those targeting incretin pathways, with the potential for combination therapies.

Management Changes

Stakeholder Impact

• Shareholders will likely view the clinical progress and capital raise positively.
• Employees may be encouraged by the company's progress and financial stability.
• Patients may benefit from the development of new therapies for cancer and obesity.
• Creditors may be reassured by the company's improved financial position.

Next Steps

• Dose the first patient in the US Phase 1 study for CRB-701 by the end of March 2024.
• Commence the Phase 1 study for CRB-601 in the summer of 2024.
• File an IND for CRB-913 by the end of 2024.
• Provide a clinical update for CSPCs dose-escalation study in mid-2024.
• Present US dose escalation data for CRB-701 by Q1 2025.

Key Dates

Keywords

oncology, CRB-701, CRB-601, CRB-913, clinical trials, antibody drug conjugate, Nectin-4, TGF, obesity, capital raise, biotechnology, pharmaceuticals